Redfaces you actually address my concerns very succinctly with...

Redfaces you actually address my concerns very succinctly with your review of the Australian market.

-Digene doing (probably) a few hundred units a month- and these boys are the market leader!

-Tam Pap HPV genotyping is going nowhere.

-Healthscope is running about 200 GBI assays a month. At $US15 that DECAN used in his modelling test that represents Australian sales of $US3,000 a month!!

Now I realise GBI is a start-up company and is not targeting the Australian market but my understanding is that health care markets in first world countries, while nuanced, actually do not differ to a substantial degree.

My question is "what is the demand differential for HPV genotyping tests in other first world countries that will drive sales of GBI's product?" I look forward to Redfaces' promised HPV market growth 'primer' answering this.